Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 avr. 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia

NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today...
03 avr. 2018 16h30 HE | Source: BeyondSpring, Inc.

BeyondSpring Files Its 2017 Annual Report on Form 20-F

NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focusing on the development of innovative cancer therapies, today...
03 avr. 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results

NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company”) (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer...
27 mars 2018 16h05 HE | Source: BeyondSpring, Inc.

BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018

NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today...
27 mars 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring Appoints Edward Dongheng Liu as Chief Financial Officer

NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies,...
19 mars 2018 08h00 HE | Source: BeyondSpring, Inc.

BeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced Neutropenia

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today...
15 mars 2018 08h00 HE | Source: BeyondSpring, Inc.

BeyondSpring Chief Medical Officer Presents at Three Prominent Industry Conferences in March 2018

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transforming immuno-oncology cancer...
07 févr. 2018 08h00 HE | Source: BeyondSpring, Inc.

BeyondSpring to Present at Upcoming Investor Conferences

NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transforming immuno-oncology cancer...
05 févr. 2018 08h30 HE | Source: BeyondSpring, Inc.

BeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia

NEW YORK , Feb. 05, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company focused on the development of transforming immuno-oncology cancer...
26 janv. 2018 08h00 HE | Source: BeyondSpring, Inc.

BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Plinabulin and Neulasta have Very Similar Grade 4 Neutropenia Incidence and Duration of Severe Neutropenia (DSN) in the Phase 2 Portion of Phase 2/3 Trial Study 105 with Docetaxel-Induced Neutropenia ...

Page précédente